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Available online 14 January 2016The KCL012 human embryonic stem cell line was derived from an embryo donated for research that carried an
autosomal dominantmutation affecting one allele of theHTT gene encoding huntingtin (46 trinucleotide repeats;
17 for the normal allele). The ICMwas isolated using laser microsurgery and plated on γ-irradiated human fore-
skinﬁbroblasts. Both the derivation and cell line propagationwere performed in an animal product-free environ-
ment. Pluripotent state and differentiation potential were conﬁrmed by in vitro and in vivo assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).In
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encoding huntingtin (~46 CAG repeats; 17 for the
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disease (Ilic et al., 2012)aryotype (G banding)
(Fig. 2)No imbalance detectedaryotype (aCGH) No imbalance detected
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(Ilic et al., 2012)iability testing Pass
luripotent markers
(immunostaining)
(Fig. 3)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
(Ilic et al., 2012)ree germ layers
differentiation in vitro
(immunostaining)
(Fig. 4)Endoderm: AFP (α-fetoprotein); Ectoderm:
TUBB3 (tubulin, β3 class III); Mesoderm: ACTA2
(actin, α2, smooth muscle) (Ilic et al., 2012)ree germ layer
differentiation in vivo
(teratomas)
(Fig. 5)Endoderm: AFP, GATA4
Ectoderm: TUBB3, GFAP (glial ﬁbrillary acidic protein)
Mesoderm: DES (desmin), Alcian Blue and periodic
acid–Schiff (PAS)-stained cartilagebling lines available KCL013Siuple undergoing IVF had 12 embryos in this particular
, whereas nine carried the mutation in HTT and were
ESC lines from two of them.We generated KCL012 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012). The ex-
pression of the pluripotencymarkers was tested after freeze/thaw cycle
(Fig. 3; Ilic et al., 2012). Differentiation potential into three germ layers
was veriﬁed in vitro (Fig. 4; Ilic et al., 2012) and in vivo (Fig. 5).
Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to researchlls) showed a normal male chromosome complement and
17; one cell 45,XY,-21.embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in themeantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.6) were created on Aug. 10, 2007.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 – R.1 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Oct. 15, 2009. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 8 – R.1. HFEA
Code of Practice Edition 7 – R.1 was in effect until Dec. 09, 2007 and Edi-
tion 8 – R.1 was in effect: Oct. 01, 2009–Apr. 06, 2010.Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Cell culture
ICM plated on mitotically inactivated HFF was cultured as de-
scribed (Ilic et al., 2012; Stephenson et al., 2012). Trophectoderm
cells were removed mechanically from outgrowth (Ilic et al., 2007;
Ilic et al., 2010). hESC colonies were expanded and cryopreserved
at the third passage.Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).banding pattern. In addition, two anomalous cells were seen, believed to be the result of
Fig. 3. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar,
25 μm.
Fig. 4. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm andα-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
Fig. 5. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not invade surrounding tissue. Sections are counterstained with hematoxylin and eosin and
speciﬁc stains are brown (immunohistochemistry) or light blue (Alcian blue). Germ layer markers: Alcian blue–PAS-stained cartilage and DES for mesoderm, TUBB3 and GFAP for
ectoderm, GATA4 and AFP for endoderm. Positive immunostaining for complex IV type II marker conﬁrms the human origin of the tumor. Scale bars are 100 μm.
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Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Fig. 3; Ilic et al., 2012; Stephenson et al., 2012).
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA ex-
traction robot according to the manufacturer's instructions. Ampliﬁca-
tion of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephenson
et al., 2012).
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
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